

Jefferies 2011 Global Healthcare Conference



London – September 27, 2011

This presentation includes forward-looking statements.

Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties including changes in business, economic competitive conditions, regulatory reforms, foreign exchange rate fluctuations and the availability of financing.

These and other risks and uncertainties are detailed in the Company's Annual Report.



Broad Pipeline

75 drug programs, 20 in clinical trials



Proven Technology

Industry's most successful antibody library technology



Increasing Market Penetration

Novel diagnostic products




Financial Strength

Profitable, strong balance sheet




Experienced Management Team

More than 80 years of pharma & biotech experience



Growing Pipeline Illustrates Successful Execution of Strategy



75 Therapeutic Antibody Programs Ongoing, 20 in Clinical Trials




Program	Partner	Indication	Discovery	Pre-clinic	Phase 1	Phase 2
MOR103 (2 programs)	-	Rheumatoid arthritis, Multiple sclerosis				
not discl.	Novartis	not discl.				
CNTO888 (2 programs)	Centocor/J&J	Cancer, Idiopathic pulmonary fibrosis				
Gantenerumab	Roche	Alzheimer's Disease				
BHQ880	Novartis	Cancer				
BYM338	Novartis	Musculoskeletal				New!
MOR208	-	Cancer				
MOR202	-	Cancer			New!	
CNTO 1959	Centocor/J&J	Psoriasis				
CNTO 3157	Centocor/J&J	Asthma				
not discl.	Centocor/J&J	Inflammation				
BAY79-4620 (ADC)	Bayer HealthCare	Cancer				
not discl.	Novartis	Ophthalmology				
not discl.	Novartis	Inflammation				
not discl.	Boehringer Ingelheim	not discl.				
not discl.	Pfizer	Cancer				
OMP-59R5	Oncomed	Cancer				
OMP-18R5	Oncomed	Cancer				
BAY94-9343 (ADC)	Bayer HealthCare	Cancer			New!	
20 Partnered Programs	Various Partners	Various Indications				
34 Programs, incl. 2 co-dev with Novartis	Various Partners	Various Indications				



65 Partnered Programs
10 Proprietary Programs




- MOR103 targets inflammatory mediator GM-CSF
- Blocks GM-CSF activity in processes central to inflammation and joint damage associated with rheumatoid arthritis




- HuCAL antibody being developed in major indications
- Phase 1b/2a trial in rheumatoid arthritis patients ongoing
- Phase 1b trial in multiple sclerosis patients planned
- Exclusive license to a US patent covering antibodies against GM-CSF for the treatment of chronic inflammatory conditions



- In-licensed from Xencor
- Comprises proprietary modification leading to rapid and sustained target cell depletion
- In clinical development for leukemia





- ▼ MOR208
- ▼ Anti-CD19 IgG1 (unmodified)
- XmAb (-) control
- Rituximab (CD20)
- Alemtuzumab (CD52)



MOR202

A New Anti-Cancer Antibody

- HuCAL antibody for multiple myeloma
- Very promising pre-clinical combination data released at ASCO
- Good cross-reactivity to a non-human primate species supports clinical trial design




Partnered Programs in Phase 2 Clinical Development

Program	Partner	Disease	Target	Status
n.d.	Novartis	n.d.	n.d.	Clinical proof of concept achieved
CNTO888	Centocor Ortho Biotech	Oncology	CCL2 (MCP-1)	Two trials ongoing, one trial completed
CNTO888	Centocor Ortho Biotech	Idiopathic pulmonary fibrosis	CCL2 (MCP-1)	One trial ongoing
Gantenerumab	Roche	Alzheimer's disease	Amyloid- β	Study in patients with prodromal AD
BHQ880	Novartis	Osteolytic bone disease	DKK-1	Early data show stimulation of bone formation (three trials ongoing)
BYM338	Novartis	Musculoskeletal	n.d.	Two phase 2 trials ongoing



Current Pipeline

Projected HuCAL Drugs on the Market




Source: MorphoSys internal statistics & Tufts Centre for the Study of Drug Development



Proven Technology Platform for Making Human Therapeutic Antibodies



HuCAL
Human Combinatorial
Antibody Library



Modular gene structure enables systematic creation of drug quality antibodies

19 HuCAL drugs in clinic

Most successful antibody library


40% Success rate from target to IND

Transforming R&D productivity



Novel Technologies For Unearthing New Antibody Drugs


Potential druggable
target



MorphoSys



**Other
technologies**



MorphoSys technologies
ensure generation of drug
candidates...

...which are missed by
methods which don't fully
"interrogate" the target

New technologies at
MorphoSys

- Slonomics
- RapMat
- RapClone



AbD Serotec Segment Complements Therapeutic Business

Antibodies for research and diagnostic markets

Diagnostic Antibodies

- Using proprietary technologies to deliver superior Dx antibodies
- Future upside via royalties

Research Antibodies

- Catalogue of 15,000+ products & custom HuCAL antibodies
- Stable and recurring cash flows

EUR millions	Guidance 2011	2010
AbD Serotec Segment Revenues	22 - 23	20.2
AbD Serotec Profit Margin	~ 4%	6%

P&L and Guidance 2011

EUR millions	2010	Guidance 2011	H1 2011
Revenues	87.0	105 – 110	66.6
Total Operating Expenses	77.4		43.5
Proprietary R&D Expenses	26.3	40 – 45	15.2
Other Operating Income	0.2		0.2
Profit from Operations	9.8	10 – 13	23.3




Balance Sheet and Shareholder Structure

Balance Sheet

EUR millions	June 30, 2011	Dec. 31, 2010
Assets		
Cash, Cash Equivalents & Marketable Securities	139.6	108.4
Other Current Assets	21.3	24.1
Total Non-Current Assets	77.6	80.0
Total Assets	238.6	212.6
Liabilities		
Total Current Liabilities	26.8	21.4
Total Non-Current Liabilities	10.0	5.3
Total Shareholders' Equity	201.8	185.9
Total Liabilities	238.6	212.6

Shareholdings by Investor Type



Shares issued: 23,034,540 (June 30, 2011)





Dr. Simon E. Moroney, CEO

- Co-founder, previously at ImmunoGen
- German Cross of the Order of Merit (2002), Bavarian State Medal for Outstanding Services to the Bavarian Economy (2009)



Jens Holstein, CFO

- Joined MorphoSys in 2011
- Formerly at Fresenius: Regional CFO for region EME of Fresenius Kabi AG; several financial and general management positions at Fresenius; and in consulting industry



Dr. Arndt Schottelius, CDO

- Joined MorphoSys in 2008
- Formerly Medical Director in Immunology at Genentech Inc.; Berlex Biosciences, USA; Schering, Germany; Charité University Hospital, Berlin




Dr. Marlies Sproll, CSO

- Joined MorphoSys in 2000, promoted to CSO in 2005
- Formerly at Boehringer Ingelheim in Vienna; Merck KGaA in Darmstadt

The Pipeline

What's Coming Up?



Expected dates for completion of clinical trials (MorphoSys estimates)





MOR103

- US patent granted on MOR103 ✓
- Complete enrollment Phase 1b/2a in rheumatoid arthritis
- Start Phase 1b in multiple sclerosis
- Start clinical study of subcutaneous formulation

MOR202

- Pre-clinical data presented at ASCO ✓
- Start Phase 1 in multiple myeloma ✓

Partners

- 1–3 INDs (✓✓)
- Data from ongoing studies



First HuCAL antibody-based diagnostic launched ✓



Further technology announcements

Thank You



www.morphosys.com

Dr. Simon Moroney
Chief Executive Officer

Phone +49 (0)89 / 899 27-311
Fax +49 (0)89 / 899 27-5311

Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR

Phone +49 (0)89 / 899 27-122
Fax +49 (0)89 / 899 27-5122
Email investors@morphosys.com